Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Book

Baricitinib

Anam Ahmad  1 , Muhammad Zaheer  2 , Fred J. Balis  3
In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan.
.
Affiliations
Free Books & Documents
Book

Baricitinib

Anam Ahmad et al.
Free Books & Documents

Excerpt

Baricitinib is a disease-modifying antirheumatic drug (DMARD) indicated for rheumatoid arthritis when conventional DMARDs prove inadequate. This medication is approved by the U.S. Food and Drug Administration (FDA) to treat adult patients with moderately to severely active rheumatoid arthritis who have not responded adequately to other DMARDs, including tumor necrosis factor antagonist therapies. Furthermore, baricitinib is FDA-approved for treating COVID-19, presenting a valuable choice in combination with other therapies for hospitalized patients, including pediatric cases necessitating supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation. This activity comprehensively reviews the indications, contraindications, mechanisms, adverse events, and other crucial aspects of baricitinib therapy within the clinical setting. This activity is tailored to meet the specific needs of an interprofessional healthcare team responsible for treating patients with rheumatoid arthritis, alopecia areata, and COVID-19.

PubMed Disclaimer

Conflict of interest statement

Disclosure: Anam Ahmad declares no relevant financial relationships with ineligible companies.

Disclosure: Muhammad Zaheer declares no relevant financial relationships with ineligible companies.

Disclosure: Fred Balis declares no relevant financial relationships with ineligible companies.

References

    1. Correction: Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study. Ann Rheum Dis. 2017 Sep;76(9):1634. - PMC - PubMed
    1. Phan K, Sebaratnam DF. JAK inhibitors for alopecia areata: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2019 May;33(5):850-856. - PubMed
    1. Kalil AC, Patterson TF, Mehta AK, Tomashek KM, Wolfe CR, Ghazaryan V, Marconi VC, Ruiz-Palacios GM, Hsieh L, Kline S, Tapson V, Iovine NM, Jain MK, Sweeney DA, El Sahly HM, Branche AR, Regalado Pineda J, Lye DC, Sandkovsky U, Luetkemeyer AF, Cohen SH, Finberg RW, Jackson PEH, Taiwo B, Paules CI, Arguinchona H, Erdmann N, Ahuja N, Frank M, Oh MD, Kim ES, Tan SY, Mularski RA, Nielsen H, Ponce PO, Taylor BS, Larson L, Rouphael NG, Saklawi Y, Cantos VD, Ko ER, Engemann JJ, Amin AN, Watanabe M, Billings J, Elie MC, Davey RT, Burgess TH, Ferreira J, Green M, Makowski M, Cardoso A, de Bono S, Bonnett T, Proschan M, Deye GA, Dempsey W, Nayak SU, Dodd LE, Beigel JH, ACTT-2 Study Group Members Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19. N Engl J Med. 2021 Mar 04;384(9):795-807. - PMC - PubMed
    1. Rubin R. Baricitinib Is First Approved COVID-19 Immunomodulatory Treatment. JAMA. 2022 Jun 21;327(23):2281. - PubMed
    1. Freitas E, Guttman-Yassky E, Torres T. Baricitinib for the Treatment of Alopecia Areata. Drugs. 2023 Jun;83(9):761-770. - PMC - PubMed

Publication types

LinkOut - more resources